2023
MGMT Promoter Methylation Predicts Overall Survival after Chemotherapy for 1p/19q-Codeleted Gliomas.
Kinslow C, Rae A, Taparra K, Kumar P, Siegelin M, Grinband J, Gill B, McKhann G, Sisti M, Bruce J, Canoll P, Iwamoto F, Horowitz D, Kachnic L, Neugut A, Yu J, Cheng S, Wang T. MGMT Promoter Methylation Predicts Overall Survival after Chemotherapy for 1p/19q-Codeleted Gliomas. Clinical Cancer Research 2023, 29: 4399-4407. PMID: 37611077, PMCID: PMC10872921, DOI: 10.1158/1078-0432.ccr-23-1295.Peer-Reviewed Original ResearchConceptsAssociated with worse survivalOverall survivalMGMT promoter statusUnmethylated MGMTWorse survivalPrognostic of progression-free survivalPromoter statusMultivariate Cox proportional hazards regression modelsWorld Health Organization gradeProgression-free survivalNational Cancer DatabaseCox proportional hazards regression modelsMGMT promoter methylationProportional hazards regression modelsGuiding treatment decisionsHazards regression modelsCourse of treatmentPredictive of responseMultiagent chemotherapyMGMT promoterCancer DatabaseMMGMTAlkylating chemotherapyChemotherapyEligible patients
2022
An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma
Hasanov E, Yeboa D, Tucker M, Swanson T, Beckham T, Rini B, Ene C, Hasanov M, Derks S, Smits M, Dudani S, Heng D, Brastianos P, Bex A, Hanalioglu S, Weinberg J, Hirsch L, Carlo M, Aizer A, Brown P, Bilen M, Chang E, Jaboin J, Brugarolas J, Choueiri T, Atkins M, McGregor B, Halasz L, Patel T, Soltys S, McDermott D, Elder J, Baskaya M, Yu J, Timmerman R, Kim M, Mut M, Markert J, Beal K, Tannir N, Samandouras G, Lang F, Giles R, Jonasch E. An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma. CA A Cancer Journal For Clinicians 2022, 72: 454-489. PMID: 35708940, DOI: 10.3322/caac.21729.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaManagement of brain metastasesBrain metastasesCell carcinomaManifestation of renal cell carcinomaResistance to systemic treatmentMultimodal treatment strategiesGuiding treatment decisionsSystemic treatmentCurrent management strategiesPoor prognosisMetastasis tumorsImmune biologyBrain metastasis tumorsRadiation treatmentTreatment strategiesInternational group of expertsCarcinomaMetastasisTreatment decisionsConsensus statementPatientsInterdisciplinary consensusUnmet patient needsLiterature review